India's Pioneer Media on TradeFairs

Largest ever edition of CPHI & PMEC India redefines Pharmaceutical Landscape

16th CPHI & PMEC India 2023, the largest edition ever is underway at the India Expo Centre in Greater Noida, Delhi – NCR.

·South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries

· Accompanying power-packed supporting programs such as 10th Annual India Pharma Awards, CEO Roundtable and ‘Women in Pharma’ Roundtable coincides with the Indian pharma landscape transitioning from a generics-oriented hub to an Innovation-driven economy.

New Delhi: Initiating a groundbreaking expedition to reshape the landscape of pharmaceutical manufacturing, CPHI & PMEC India 2023 commenced on 28th November at the India Expo Centre in Greater Noida, Delhi – NCR. Mirroring the trajectory of the flourishing Indian pharma sector, this 16th edition stands as the largest yet, poised to revolutionize the pharmaceutical industry.

 It provides an unparalleled platform for stakeholders to participate in extensive dialogues covering pharma machinery, packaging, analytical instruments, laboratory technologies, equipment, ancillaries, ingredients, and beyond.

Igniting collaborative growth across the Pharmaceutical Ecosystem

 The 16th edition of CPHI & PMEC India builds on the success of the Pharma Leaders’ Golf and the CPHI Pre-Connect Congress just prior to the show. Themed “Integrate Innovation, Sustainability, and Growth,” this edition aimed to align and shape the roadmap for the next decade of Indian Pharma.

The signature trade expo, South Asia’s largest and most comprehensive pharma congregation, brought together a vast assembly of industry experts, top manufacturers, the buyer’s community, policy advisors, and key stakeholders, uniting suppliers, innovators, and pharmaceutical leaders.

The grand inauguration ceremony was marked by the presence of key dignitaries Dr Veeramani S.V, Vice-Chairman PHARMEXCIL; Mr Harish Jain, President FOPE; Mr Raja Bhanu, Executive Director PHARMEXCIL, Ms Margaret Ma, President & CEO – Informa Markets Asia; Mr Chris Eve, Executive. Vice President – Informa Markets Asia; Mr Adam Anderson, Executive Vice President – Pharma, Informa Markets; Mr Yogesh Mudras, Managing Director, Informa Markets in India; Mr Rahul Deshpande, Senior Group Director, Informa Markets in India, and Mr Ranjith Paul, Group Director, Informa Markets in India.

The Indian pharmaceutical industry is on a compelling growth trajectory, evidenced by an 8% year-to-date increase in exports and a remarkable 29% surge in October alone. This growth is propelled by expanding market opportunities, heightened demand in the USA, and critical shortages of medicines in the US and Europe. Despite challenges in CIS countries, the global reception of Indian pharmaceuticals remains positive. The domestic market has exhibited impressive growth, exceeding 10%. Driven by this momentum, I am confident in reaching the 130 billion mark by 2030, advocating for a consistent 10% growth in both domestic and export markets. Expos like CPHI & PMEC India are instrumental in propelling our industry forward, fostering innovation, and reinforcing India’s position on the global pharmaceutical stage.”

 Dr. Veeramani S.V., Chairman – Pharmexcil

“While discussions revolve around India’s pharmaceutical landscape in 2030, our industry is visionary, setting its sights on India in 2047. Aligned with Prime Minister Narendra Modi’s concept of Amrit Kal, we anticipate a trajectory of sustained growth. Exceeding the projected $130 billion mark, the Department of Pharmaceuticals (DOP) envisions an ambitious $200 billion goal. Achieving this necessitates regulatory reforms to foster industry growth, address patient needs, and promote disruptive innovation, as we learned from the pandemic. Regarding the pharmaceutical sector’s outlook, we foresee stable double-digit growth, around 13-14%, conditional on consistent policies that streamline doing business. CPHI serves as a crucial platform to deliberate on achievements, challenges, and influence regulators for favourable business conditions.”

Mr Anil Matai, Director General, OPPI


A Global Showcase 

The current edition is estimated to boast over 50,000 visitors and 1,500 exhibitors from 80+ countries, showcasing a diverse range of 10,000+ products. Their collective presence emphasizes the significance of CPHI & PMEC India as a pivotal industry event, reinforcing its role in boosting and facilitating the pharmaceutical sector. Notable exhibitors included Dr. Reddy’s Laboratories Ltd; Biocon Ltd; Glenmark Lifesciences Ltd; Piramal Pharma Solutions; Hetero Labs Limited; ACG; IMA Industria Macchine Automatiche S.P.A; Fette Compacting Machinery India Pvt. Ltd., Supriya Lifescience Ltd and Ace Technologies & Packaging Systems Pvt. Ltd. among others.

Industry Associations Support 

The CPHI and PMEC India Expo is comprehensively supported by industry associations such as BDMA (Bulk Drug Manufacturing Association), FOPE (Federation of Pharma Entrepreneurs), KDPMA (Karnataka Drugs and Pharmaceuticals Manufacturers’ Association), OPPI (Organisation of Pharmaceutical Producers of India), and PharmExcil.

Government-approved schemes in 2021 aim to develop substitute APIs, support global suppliers, and upgrade MSME sector standards to WHO-GIMP. This transformation aligns with the industry’s progress highlighted at CPHI and PMEC India 2023, where Mr. Eshwar Reddy, BDMA’s Executive Director, emphasized India’s robust performance in the 2023 CPHI Pharma Index, scoring 7.187. This underscores the industry’s drive for innovation and self-sufficiency, positioning these events as crucial platforms to showcase advancements, foster collaborations, and drive growth.”

 “India’s pharmaceutical prowess, contributing a formidable 20% to global exports, achieved a remarkable USD 25.3 billion (INR 2.1 lakh crores) in the 2022–2023 fiscal year. Robust R&D investments from both domestic and international players drive innovation, a pivotal force propelling market expansion. With government backing, exemplified by Rs. 5,000 crores in R&D incentives, India emerges as a key leader in global healthcare development. The CPHI & PMEC India Expo, along with ancillary events during the India Pharma Week, stands as a premier global platform, fostering connections and collaborations within the pharmaceutical community. This year, hosting the largest-ever expo edition, it symbolizes India’s ascent as a monumental pharma superpower.”

Mr. Yogesh Mudras, Managing Director, Informa Markets in India


 Leading Innovation & Growth

Post Covid, the pharmaceutical industry has undergone a transformative shift, witnessing a pronounced collaboration between the government and the sector. This newfound synergy is particularly evident in the positive light cast upon technology companies with platform and services capabilities.

Positioned at the intersection of innovation and necessity, these companies introduce cutting-edge technology solutions, including wearables, sensors, radio-frequency identification, remote monitoring systems, Generative artificial intelligence (AI), and Business Processes as a Service (BPaaS) models. These advancements play a crucial role in facilitating decentralized and home-based trials, a trend that gained momentum in response to the disruptions caused by the pandemic.

Looking ahead, the Active Pharmaceutical Ingredients (API) Market in India is poised for substantial growth, projected to reach USD 29 billion (INR 2.4 lakh crores) by 2030 with an anticipated CAGR of 8.31%. This promising trajectory is further fueled by the introduction of the PLI Scheme, a strategic initiative that actively promotes local manufacturing of APIs, Key Starting Materials (KSMs), and Drug Intermediaries, reinforcing India’s position as a key player in the global pharmaceutical landscape.


Unveiling Excellence in Pharma

Following the last few days precursors to the expo, The Pharma Leaders’ Golf at the renowned Jaypee Wishtown Golf Course brought together around 40 esteemed pharma leaders for informal networking amid a round of golf and the Pre-Connect Congress, which drew in 150 pharma professionals with insights from 20 distinguished speakers, the prestigious ‘India Pharma Week’ was unveiled.

 This curated series of exclusive events aims to captivate industry leaders and experts through diverse formats. As CPHI & PMEC India presents the latest technological advancements, the meticulously designed Pharma Leaders’ Roundtable emerged as a platform to explore innovations within the pharmaceutical sector. The focus of the talks was on charting a path for Indian pharmaceutical companies to attain global leadership by generating substantial value. Delving into crucial topics, the discussions centred around ‘Strengthening pharmaceutical innovation for broader reach, addressing unmet clinical needs, and embracing next-generation possibilities,’ as well as ‘Revolutionizing packaging, ensuring market access, and enhancing drug affordability.

Alongside, the India Pharma Awards celebrated excellence and innovation within the pharmaceutical space, acknowledging outstanding pharma brands for their noteworthy contributions to the industry. Day 2 will see the Women in Pharma Roundtable, which is an initiative aimed at acknowledging and celebrating the significant and continued contribution of women to the pharmaceutical industry in a closed-door roundtable discussion.

Over the next three days, this grand spectacle will keenly strive to shape the future landscape of the pharmaceutical industry through a seamless convergence of expertise from both the public and private sectors.

Mr. Sanjeev Jain, Founder of Akums Drugs & Pharmaceuticals Ltd, shared, “Our collaboration with Biophore on a rare disease product made a significant impact at our CPHI India stall. Despite the limited significance of the rare disease industry, the government’s pivotal role, especially in rural areas, is crucial. Offering our product to the government at less than 500 (compared to the 70,000 market rate) is pivotal. CPHI is essential for connecting with a diverse customer base. Last year, we had over 3000 visitors, and this year, we aim to surpass 4000 visits in a day. Our unwavering goal is a minimum 15 percent year-on-year growth, a target we consistently and diligently pursue, often achieving success.” 

Mr Karan Singh, Managing Director at ACG, expressed excitement about unveiling the AF330 at CPHI PMEC this year, stating, “As we thrive to make it better for manufacturers in the pharmaceutical industry, this design ensures efficiency, minimal maintenance and speed – optimizing performance for manufacturers.” He added, “A revolutionary step in capsule filling capability, it embodies the next generation of manufacturing excellence, setting new standards in efficiency and high productivity in smallest footprint. We are eager to showcase its groundbreaking features over the next few days.” 

CPHI & PMEC India 2023 seamlessly integrates into Informa Markets India’s 4th edition of the Festivity of Business campaign, marking a high season of economic celebration. This year’s initiative encompasses a diverse array of over 40 events, including ten signature Expos, Conferences, Industry Awards, Buyer-Seller Meets, and Training programs, all set to propel India to new heights.

About the CPHI & PMEC expo:

Originating from CPHI Worldwide – CPHI India has become South Asia’s leading Pharma meeting place covering every step of the supply chain from drug discovery to finished dosage, encompassing CROs, CMOs, and manufacturers of API, Generics, Excipients and Drug formulation, Fine chemicals, Biosimilars, Finished Formulations, Lab chemicals, and Biotechnology.

PMEC, on the other hand, includes manufacturers of Pharma Machinery and Equipment, Analytical Equipment, Automation & Robotics, Packaging Equipment & Supplies, Plant / Facility Equipment, Automation & Controls, Processing Equipment, RFID, Tableting / Capsule fillers, Cleanroom equipment, Filling equipment and Laboratory products.